BLASYRINGE
Approved
Jan 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEGINTRON (peginterferon alfa-2b) is a pegylated interferon alpha product administered as a subcutaneous injection, developed by Merck & Co. It is a biological therapeutic indicated for chronic viral hepatitis C and hepatitis B infections. The drug works by enhancing immune response through interferon alpha signaling to combat persistent viral infections.
LOE Approaching
Declining
Product approaching loss of exclusivity with moderate competitive pressure (30/100); teams likely focused on transition planning and pipeline support rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations
Started Oct 2026
30 enrolled
RopeginterferonAlfa-2bAzacitidine+1 more
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Started Sep 2026
35 enrolled
Atypical Chronic Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm+2 more
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis
Started Aug 2026
15 enrolled
Myelofibrosis
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Started Sep 2022
429 enrolled
Polycythemia Vera
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
Started Aug 2022
20 enrolled
Chronic Hepatitis B InfectionChronic Hepatitis D Infection
Worked on PEGINTRON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.